JR-171 (lepunafusp alfa) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病2

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04453085
(ClinicalTrials.gov)
October 28, 20214/6/2020An Extension Study of JR-171-101 Study in Patients With MPS IAn Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis IDrug: JR-171 (lepunafusp alfa)JCR Pharmaceuticals Co., Ltd.NULLActive, not recruitingN/AN/AAll14Phase 1/Phase 2United States;Brazil;Japan
2NCT04227600
(ClinicalTrials.gov)
September 1, 202027/12/2019A Study of JR-171 in Patients With Mucopolysaccharidosis IPhase I/II Study of JR-171 ? Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis IDrug: JR-171 (lepunafusp alfa)JCR Pharmaceuticals Co., Ltd.NULLCompleted0 YearsN/AAll19Phase 1/Phase 2United States;Brazil;Japan